SYTHEIA

Class [5]
Pharmaceutical Products

Pharmaceuticals; pharmaceutical preparations; preparations for the treatment of ocular disease; preparations for the treatment of retinitis pigmentosa; Pharmaceutical compositions; vaccines; vaccine preparations; preparations for gene therapy; preparations for cell therapy; gene therapy products; genetically engineered tissues for transplant purposes; recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; recombinant adeno-associated virus (rAAV) vector for treating Retinitis Pigmentosa; recombinant nucleic acid for treating ocular diseases; recombinant nucleic acid for treating Retinitis Pigmentosa; recombinant DNA for treating ocular diseases; recombinant DNA for treating Retinitis Pigmentosa; recombinant rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration.